Literature DB >> 6831625

Time dependency of adriamycin and adriamycinol kinetics.

P Gil, R Favre, A Durand, A Iliadis, J P Cano, Y Carcassonne.   

Abstract

Adriamycin was administered by IV injection to seven patients with various solid tumors at a dose of 30 mg/m2 during successive courses. Extraction was carried out by the SEP-PAK method for plasma and by solvents for urine. Plasma and urinary levels of adriamycin and adriamycinol were determined by high-performance liquid chromatography over 72-h period after injection. Pharmacokinetic parameters for adriamycin and adriamycinol were calculated for each course of treatment. The results show significant inter- and intra-individual variations in the kinetics and elimination of both compounds. The analysis of pharmacokinetic data reveals a wide variability in the fluctuations observed during the successive courses in different patients. This study confirms the time-dependency of ADR kinetics.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6831625     DOI： 10.1007/bf00446223

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  21 in total

1.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin.

Authors:  W A Creasey; L S McIntosh; T Brescia; O Odujinrin; G T Aspnes; E Murray; J C Marsh
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

2.  Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease.

Authors:  J J Wang; E Cortes; L F Sinks; J F Holland
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

3.  Pharmacokinetics and metabolism of adriamycin in man.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

4.  Distribution and excretion of adriamycin in man.

Authors:  G Di Fronzo; L Lenaz; G Bonadonna
Journal:  Biomedicine       Date:  1973-04-10

5.  Clinical trials with adriamycin.

Authors:  E Middleman; J Luce; E Frei
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

6.  Rapid analytic method for adriamycin and metabolites in human plasma by a thin-film fluorescence scanner.

Authors:  E Watson; K K Chan
Journal:  Cancer Treat Rep       Date:  1976-11

7.  Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay.

Authors:  N R Bachur; C E Riggs; M R Green; J J Langone; H Van Vunakis; L Levine
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

8.  Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.

Authors:  K K Chan; R T Chlebowski; M Tong; H S Chen; J F Gross; J R Bateman
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

9.  Effects of prior therapy on plasma levels of adriamycin during subsequent therapy.

Authors:  T Gessner; J Robert; W Bolanowska; B Hoerni; M Durand; H Preisler; J Rustum
Journal:  J Med       Date:  1981

10.  Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Authors:  E Piazza; M G Donelli; M Broggini; C Sessa; N Natale; L Ottolenghi; S Marsoni; A Libretti; C Mangioni; L Morasca
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep
View more
  18 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

2.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer.

Authors:  M H Bronchud; J M Margison; A Howell; M Lind; S B Lucas; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Pharmacokinetics of doxorubicin in sarcoma patients.

Authors:  J Robert; N B Bui; P Vrignaud
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 6.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

7.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

8.  Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.

Authors:  D B Smith; J M Margison; S B Lucas; P M Wilkinson; A Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence.

Authors:  R Erttmann; N Erb; A Steinhoff; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).

Authors:  P Dodion; T A Davis; M Rozencweig; N Crespeigne; Y Kenis; N R Bachur
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.